Nuformix Plc (1RT) AI Stock Analysis

2 Followers

Nuformix Plc

(Frankfurt:1RT)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Debt-free balance sheetThe absence of debt limits interest obligations and refinancing exposure, giving Nuformix greater flexibility than a similarly loss-making company with leverage. This provides some capacity to direct future funding toward development activities, although the small asset base remains a constraint.

Negative Factors

No recent revenuePersistent zero revenue indicates that Nuformix has not yet established a meaningful commercial or partnering income stream. This leaves near-term progress dependent on advancing drug candidates toward licensing, milestones, or royalties rather than funding operations through recurring sales.

Nuformix Plc (1RT) vs. iShares MSCI Germany ETF (EWG)

Not enough price history over this period.

Market Cap: EUR 2.61M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -2.1
Beta (1Y): -0.61
Revenue Growth: ―
EPS Growth: 94.12%
Country: Germany
Employees: 3
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Nuformix Plc Business Overview & Revenue Model

Company Description

Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes in developing therapies for fibrotic diseases and cancer, primarily through the innovative strategy of drug repurposing. Its current development portfolio includes NXP001...

Nuformix Plc Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:1RT against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GB:IMM	44Neutral	GBP 21.96M	-2.60	-559.87%	―	―	5.62%
GB:FUM	42Neutral	GBP 2.74M	-0.30	-152.41%	―	-70.77%	60.39%
GB:TCF	42Neutral	GBP 4.64M	-1.70	-93.92%	―	―	55.56%
GB:HEMO	41Neutral	GBP 44.14M	-3.34	-409.57%	―	―	18.57%
GB:OPTI	41Neutral	GBP 5.78M	-1.35	-77.85%	―	11.90%	-2864.29%

* Healthcare Sector Average

Performance Comparison

DE:1RT and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:1RT	Nuformix Plc	―	―	―
GB:TCF	Evgen Pharma	0.17	-0.04	-19.05%
GB:FUM	Futura Medical	0.19	-2.13	-91.81%
GB:IMM	ImmuPharma plc	3.25	-7.25	-69.00%
GB:OPTI	OptiBiotix Health	5.60	-2.15	-27.74%
GB:HEMO	Hemogenyx Pharmaceuticals Plc	605.00	-371.00	-38.01%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Nuformix Plc AI Stock Analysis